Stocks and Investing
Stocks and Investing
Fri, November 18, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, November 17, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mark Massaro Maintained (XGN) at Strong Buy with Decreased Target to $7 on, Nov 17th, 2022
Mark Massaro of BTIG, Maintained "Exagen Inc." (XGN) at Strong Buy with Decreased Target from $10 to $7 on, Nov 17th, 2022.
Mark has made no other calls on XGN in the last 4 months.
There is 1 other peer that has a rating on XGN. Out of the 1 peers that are also analyzing XGN, 0 agree with Mark's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mark
- Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $7 on, Tuesday, November 15th, 2022
Contributing Sources